Along with the complexities of vaccine and viral-based gene therapy process development comes the need for analytical techniques that can help assess quality parameters, especially in real-time. LumaCyte’s Laser Force Cytology (LFC) instrument, Radiance®, provides rapid and accurate measurement of quality attributes such as viral titer and infectivity, helping to accelerate the development and production of these advanced therapies.

Join Catalent and LumaCyte to learn how:

• Label-free analysis can provide near real-time infectivity measurements
• Timely, cost-effective measurements help process optimization and scale-up
• LFC automates and accelerates viral titer and infectivity assays
• LFC results correlate with ddPCR, end-point dilution (TCID50), and plaque assays.

Traditional infectivity methods, including the TCID50 and viral plaque assays, can take days to weeks, with the results often suffering from subjectivity and requiring significant resources. Radiance® data will be presented on rapid and low error adenovirus and baculovirus infectivity measurements as well as AAV transfection monitoring.